GET DAILY SIGNALSWhy Is Coherus Oncology (CHRS) Stock Down -10.7% Today?
Key Takeaways
- CHRS shares fell roughly 10.7%, or about $0.09, to near $0.73, after closing around $0.82 in the previous session.
- Primary catalyst: Third-quarter 2026 results reported after Monday's close, including a revenue miss and a going-concern disclosure in the company's 10-Q filing.
- Secondary drivers: Management cut full-year LOQTORZI revenue guidance and announced a roughly 30% workforce reduction.
- Balance-sheet pressure: Cash and investments fell to $83.6 million, leaving a cash runway of less than 12 months.
- Broader context: The micro-cap biotech is trading near its 52-week low amid a risk-off tone in speculative growth equities.
- What traders are watching: Potential financing, ex-U.S. partnering, and fourth-quarter LOQTORZI sales execution.
- For additional detail on Price Targets, Earnings, and Forecast for CHRS, explore these dedicated pages.
- Explore Trending AI Robots to see which AI-driven trading strategies are performing best in current market conditions.
Opening Summary
Coherus Oncology, Inc. (formerly Coherus BioSciences), a commercial-stage immuno-oncology company focused on its approved PD-1 inhibitor LOQTORZI (toripalimab) and its clinical-stage candidate tagmokitug, saw CHRS shares slide about 10.7% on Tuesday to roughly $0.73, extending a sharp post-earnings selloff from a prior close near $0.82. The decline followed the company's third-quarter 2026 report released after Monday's close, which paired an earnings beat on the bottom line with a top-line miss, reduced full-year guidance, and a disclosure that its cash runway has fallen below 12 months.
Q3 Results Miss on the Top Line
The market reaction was driven first by the earnings report. Coherus posted third-quarter net revenue of about $14.27 million, up from $11.57 million a year earlier but short of the roughly $15.9 million analysts had expected. GAAP net loss from continuing operations narrowed to $38.9 million, or $0.25 per share, while non-GAAP loss came in at about $0.20 per share. Although the loss narrowed year over year, the revenue shortfall and, more importantly, the trajectory of its only marketed drug, LOQTORZI, dominated investor attention.
Slowing LOQTORZI Growth and a Guidance Cut
LOQTORZI revenue reached $14.0 million in the quarter, up 25% year over year but only 3% sequentially — well below the 10% to 15% quarterly growth management had previously targeted. Executives attributed the deceleration to lumpy patient flow and slower new-patient starts in several territories. In response, Coherus lowered its full-year 2026 LOQTORZI revenue outlook to a range of $54 million to $57 million, down from $57 million to $62 million, and pointed to a roughly $15 million fourth quarter. The cut reinforced concerns that the company's path to cash-flow breakeven remains uncertain.
Going-Concern Warning and Cash Runway Pressure
The sharpest selling pressure came from the balance sheet. Coherus ended September with $83.6 million in cash, equivalents, and marketable securities, down from $105.3 million at the end of June, and its 10-Q included going-concern language indicating a cash runway of less than 12 months absent cost reductions, milestone payments, or partnership proceeds. Management is pursuing a 30% headcount reduction (from roughly 140 to 100 employees) expected to save $6 million to $7 million per quarter, and it is exploring ex-U.S. partnering for tagmokitug and potential UDENYCA divestiture milestone payments. Still, investors weighed the near-term dilution or financing risk posed by the constrained liquidity position.
Strategic Pivot to Esophageal Cancer
Offsetting some of the pessimism was a strategic update. Coherus said it will focus tagmokitug/toripalimab development on esophageal cancer, citing encouraging second-line data — including a 33.3% confirmed objective response rate versus a chemotherapy benchmark near 10% — and an expedited regulatory path. While the clinical signal was viewed as positive, it arrives as the balance sheet has become the dominant concern for shareholders.
Market Context and Trading Activity
Trading volume in CHRS was elevated relative to its recent average, consistent with an earnings-driven repricing in a low-priced, micro-cap name. The stock, with a market capitalization near $126 million, remains under pressure near its 52-week low after a prolonged downtrend that has erased more than a third of its value over the past year. The move diverged from the broader market, underscoring that the decline was company-specific rather than a function of a sector-wide or index-level pullback.
What Comes Next for CHRS
Investors will be watching several near-term signposts for CHRS. Fourth-quarter LOQTORZI sales will test whether the company can reaccelerate growth toward its new $15 million quarterly target. Financing developments — including ex-U.S. partnering discussions for tagmokitug, UDENYCA milestone outcomes, and any potential capital raises — are central to resolving the going-concern overhang. The company also plans FDA discussions in 2027 on the tagmokitug dose and second-line esophageal cancer study design. Risks remain tilted to the downside if revenue execution stalls or the cash runway tightens further, while successful nondilutive financing or clinical milestones could stabilize sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently outperforming across thousands of tickers. While Tickeron offers hundreds of bots spanning different strategies, timeframes, performance metrics, and traded symbols, only the strongest performers under today's market conditions are featured in this section. Traders seeking an algorithmic edge may find it useful to explore these tools as part of a broader research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
CHRS's RSI Indicator ascending out of oversold territory
The RSI Oscillator for CHRS moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement